@George1972
Awesome find.
The "cancer" story of ATL1102 is yet to begin - that will really get the market interested.
________________
"The world of chronic lymphocytic leukemia (CLL) research is awash with prognostic markers. However, very few of the current group play a clearly defined role in the pathology of this disease and even fewer represent a tractable therapeutic target. One such marker that fulfils both of these criteria is the integrin CD49d...."
.
Where others have failed will Atl1102 succeed ?, page-703
-
- There are more pages in this discussion • 394 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.002(2.04%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $50.98K | 508.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 69109 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 249627 | 5 |
View Market Depth
| Last trade - 16.10pm 20/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |